Akcea Therapeutics, Inc. (AKCA): Price and Financial Metrics

Akcea Therapeutics, Inc. (AKCA): $18.17

0.03 (+0.17%)

POWR Rating

Component Grades








Add AKCA to Watchlist
Sign Up

Industry: Biotech




in industry

AKCA Price/Volume Stats

Current price $18.17 52-week high $21.70
Prev. close $18.14 52-week low $8.00
Day low $18.13 Volume 815,300
Day high $18.17 Avg. volume 361,806
50-day MA $15.31 Dividend yield N/A
200-day MA $15.48 Market Cap 1.85B

AKCA Stock Price Chart Interactive Chart >

Akcea Therapeutics, Inc. (AKCA) Company Bio

Akcea Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. The company was founded in 2014 and is based in Cambridge, Massachusetts.

AKCA Latest News Stream

Event/Time News Detail
Loading, please wait...

AKCA Latest Social Stream

Loading social stream, please wait...

View Full AKCA Social Stream

Latest AKCA News From Around the Web

Below are the latest news stories about Akcea Therapeutics Inc that investors may wish to consider to help them evaluate AKCA as an investment opportunity.

Akcea's Waylivra secures NICE recommendation for ultra-rare inherited disorder

Akcea Therapeutics (AKCA), majority-owned affiliate of Ionis Pharmaceuticals (IONS), announces that the National Institute for Health and Care Excellence ((NICE)) has issued a positive Final Evaluation Document for WAYLIVRA (volanesorsen) for the treatment of Familial Chylomicronaemia Syndrome ((FCS)) for routine care on the National Health Service in England.FCS is a rare, inherited disorder characterised...

Seeking Alpha | September 18, 2020

WAYLIVRA▼® (volanesorsen), the First and Only Therapy for FCS, an Ultra-Rare and Life-Threatening Condition, to Be Available on the NHS in England

LONDON--(BUSINESS WIRE)--Akcea Therapeutics UK Ltd., a subsidiary of Akcea Therapeutics Inc. (NASDAQ: AKCA), announced today that the National Institute for Health and Care Excellence (NICE) has issued a positive Final Evaluation Document (FED) for volanesorsen for the treatment of Familial Chylomicronaemia Syndrome (FCS) for routine care on the National Health Service (NHS) in England. FCS is an under-recognised condition characterised by extremely high triglycerides levels (10 to 100 times no

Business Wire | September 18, 2020

Akcea shoots up 59% on positive vupanorsen data; Ionis acquires remaining stake for $500M

Akcea Therapeutics (AKCA), a majority-owned affiliate of Ionis Pharmaceuticals (IONS) presents data from the Phase 2 clinical trial of vupanorsen (AKCEA-ANGPTL3-LRx) at the ESC Congress 2020.Vupanorsen, an investigational antisense therapy being developed using Ionis' LIgand Conjugated Antisense technology platform to reduce the production of angiopoietin-like 3 (ANGPTL3) protein from the liver which is...

Seeking Alpha | August 31, 2020

Akcea Therapeutics Rallies After Majority Owner Ionis Agrees To Buy Remaining Stake

Akcea Therapeutics Inc (NASDAQ: AKCA ) shares were rallying strongly Monday following a buyout deal. The Ionis, Akcea Deal Terms: Akcea and its majority owner Ionis Pharmaceuticals Inc (NASDAQ: IONS ) announced a definitive agreement under which Ionis will acquire the 24% stake in Akcea it does not already own for $18.15 per share — about 60% higher than Akcea's Friday closing price. The total transaction value is about $500 million. The deal has been approved by the boards of both companies and … Full story available on Benzinga.com

Benzinga | August 31, 2020

Akcea Announces Approval for Reimbursement of TEGSEDI® (inotersen) in Austria for Treatment of Hereditary Transthyretin Amyloidosis with Polyneuropathy

Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that the Main Association of Austrian Social Security Institutions (Dachverband der Österreichischen Sozialversicherungsträger, or DV) has granted approval for the national reimbursement of TEGSEDI® (inotersen) for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin (hATTR) amyloidosis.

Yahoo | July 22, 2020

Read More 'AKCA' Stories Here

AKCA Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year N/A
5-year -37.32%
2023 N/A
2022 N/A
2021 N/A
2020 0.00%
2019 -43.80%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!